3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
4
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
35
Recurrence
27
Multiple Myeloma
27
Leukemia, Lymphocytic, Chronic, B-Cell
27
Lymphoma, Non-Hodgkin
25
Lymphoma
20
Neoplasms
16
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, B-Cell
15
Lymphoma, Follicular
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma, Mantle-Cell
13
Leukemia
13
Carcinoma, Non-Small-Cell Lung
13
Stomach Neoplasms
11
Ovarian Neoplasms
9
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Head and Neck Neoplasms
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Myelodysplastic Syndromes
6
Melanoma
6
Lymphoma, B-Cell, Marginal Zone
6
Breast Neoplasms
6
Liposarcoma, Myxoid
5
Colorectal Neoplasms
5
Burkitt Lymphoma
5
Interventions
10-propargyl-10-deazaaminopterin
12
Cyclophosphamide
8
Prednisone
7
belinostat
6
Vincristine
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Doxorubicin
6
Brentuximab Vedotin
5
romidepsin
4
mogamulizumab
4
darinaparsin
4
Vitamin B 12
4
Gemcitabine
4
Folic Acid
4
selinexor
3
denileukin diftitox
3
Nivolumab
3
Injections
3
Bendamustine Hydrochloride
3
tislelizumab
2
tipifarnib
2
tenalisib
2
duvelisib
2
Rituximab
2
Lenalidomide
2
HBI-8000
2
Fenretinide
2
E7777 fusion protein
2
AFM13
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell, Peripheral
×
fludarabine
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts